Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | -$0.17 | $0.02 | -$0.08 |
Q2 2025 | 1 | $0.00 | $0.00 | $0.00 |
Q3 2025 | 1 | $0.02 | $0.02 | $0.02 |
Q4 2025 | 1 | -$0.10 | -$0.10 | -$0.10 |
Q1 2026 | 1 | -$0.02 | -$0.02 | -$0.02 |
Q2 2026 | 1 | $0.05 | $0.05 | $0.05 |
Q3 2026 | 1 | $0.07 | $0.07 | $0.07 |
Q4 2026 | 1 | -$0.08 | -$0.08 | -$0.08 |
Fulgent Genetics, Inc. last posted its earnings results on Friday, November 8th, 2024. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $-0.19 by $0.5. The company had revenue of 71.74 M for the quarter and had revenue of 289.21 M for the year. Fulgent Genetics, Inc. has generated $-6 earnings per share over the last year ($-5.63 diluted earnings per share) and currently has a price-to-earnings ratio of -3.49. Fulgent Genetics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/08/2024 | Q3 2024 | -$0.19 | -$0.48 | -0.29 | $71.72 M | $71.74 M |
08/02/2024 | Q2 2024 | -$0.31 | -$0.29 | 0.02 | $69.07 M | $71.03 M |
05/03/2024 | Q1 2024 | -$0.33 | -$0.45 | -0.12 | $64.49 M | |
02/28/2024 | Q4 2023 | -$0.30 | -$4.30 | -4 | $70.51 M | |
11/03/2023 | Q3 2023 | -$0.32 | -$0.44 | -0.12 | $64.42 M | $84.69 M |
08/04/2023 | Q2 2023 | -$0.33 | -$0.38 | -0.05 | $62.48 M | $67.85 M |
05/05/2023 | Q1 2023 | -$0.45 | -$0.54 | -0.09 | $66.17 M | |
02/28/2023 | Q4 2022 | -$0.56 | -$0.81 | -0.25 | $67.70 M | |
11/07/2022 | Q3 2022 | $0.17 | $0.04 | -0.13 | $91.36 M | $105.66 M |
08/04/2022 | Q2 2022 | $0.73 | $0.38 | -0.35 | $122.70 M | $125.34 M |
05/05/2022 | Q1 2022 | $5.09 | $320.27 M | |||
02/28/2022 | Q4 2021 | $3.48 | $251.67 M | |||
11/09/2021 | Q3 2021 | $3.25 | $4.13 | 0.88 | $264.00 M | $227.87 M |
08/09/2021 | Q2 2021 | $2.74 | $197.34 M | $153.62 M | ||
05/07/2021 | Q1 2021 | $6.96 | $359.43 M | |||
03/08/2021 | Q4 2020 | $6.55 | $294.98 M | |||
11/09/2020 | Q3 2020 | $0.55 | $2.11 | 1.56 | $48.46 M | $101.72 M |
08/04/2020 | Q2 2020 | $0.15 | $10.02 M | $17.27 M | ||
05/06/2020 | Q1 2020 | -$0.09 | $7.75 M | |||
03/13/2020 | Q4 2019 | -$0.02 | $8.39 M |
Fulgent Genetics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
In the previous quarter, Fulgent Genetics, Inc. (:FLGT) reported $0.31 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.19 by $0.5.
The conference call for Fulgent Genetics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Fulgent Genetics, Inc.'s latest earnings report can be read online.
Fulgent Genetics, Inc. (:FLGT) has a recorded annual revenue of $289.21 M.
Fulgent Genetics, Inc. (:FLGT) has a recorded net income of $289.21 M. Fulgent Genetics, Inc. has generated $-5.63 earnings per share over the last four quarters.
Fulgent Genetics, Inc. (:FLGT) has a price-to-earnings ratio of -3.49 and price/earnings-to-growth ratio is 4.79.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED